Neurocrine Biosciences Stock Buy Hold or Sell Recommendation
| NBIX Stock | USD 110.75 1.76 1.61% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Neurocrine Biosciences is 'Strong Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Neurocrine Biosciences given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Neurocrine Biosciences, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Neurocrine Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide. In addition, we conduct extensive research on individual companies such as Neurocrine and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Neurocrine Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Neurocrine |
Execute Neurocrine Biosciences Buy or Sell Advice
The Neurocrine recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Neurocrine Biosciences. Macroaxis does not own or have any residual interests in Neurocrine Biosciences or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Neurocrine Biosciences' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Neurocrine Biosciences Trading Alerts and Improvement Suggestions
| Neurocrine Biosciences generated a negative expected return over the last 90 days | |
| Neurocrine Biosciences has a strong financial position based on the latest SEC filings | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Brokerages Set Neurocrine Biosciences, Inc. Price Target at 166.90 |
Neurocrine Biosciences Returns Distribution Density
The distribution of Neurocrine Biosciences' historical returns is an attempt to chart the uncertainty of Neurocrine Biosciences' future price movements. The chart of the probability distribution of Neurocrine Biosciences daily returns describes the distribution of returns around its average expected value. We use Neurocrine Biosciences price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Neurocrine Biosciences returns is essential to provide solid investment advice for Neurocrine Biosciences.
| Mean Return | -0.18 | Value At Risk | -3.11 | Potential Upside | 2.19 | Standard Deviation | 2.78 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Neurocrine Biosciences historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Neurocrine Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Neurocrine Biosciences, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Neurocrine Biosciences back and forth among themselves.
| Shares | Wellington Management Company Llp | 2024-12-31 | 1.5 M | Jpmorgan Chase & Co | 2024-12-31 | 1.4 M | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 1.1 M | Goldman Sachs Group Inc | 2024-12-31 | 983.8 K | Northern Trust Corp | 2024-12-31 | 981.9 K | Amvescap Plc. | 2024-12-31 | 949.5 K | Bnp Paribas Investment Partners Sa | 2024-12-31 | 944.7 K | Orbimed Advisors, Llc | 2024-12-31 | 938.1 K | Dsm Capital Partners Llc | 2024-12-31 | 932.6 K | Blackrock Inc | 2024-12-31 | 14.8 M | Vanguard Group Inc | 2024-12-31 | 10.1 M |
Neurocrine Biosciences Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 74.8M | 153.7M | (73.3M) | (11.6M) | (18.1M) | (17.2M) | |
| Free Cash Flow | 217.6M | 233.1M | 322.9M | 361.6M | 557.2M | 585.1M | |
| Depreciation | 8.6M | 10.9M | 15.6M | 21.3M | (2.7M) | (2.6M) | |
| Other Non Cash Items | 61.2M | 800K | 44.5M | (46.9M) | 184.4M | 193.6M | |
| Capital Expenditures | 10.9M | 23.4M | 16.5M | 28.3M | 38.2M | 40.1M | |
| Net Income | 407.3M | 89.6M | 154.5M | 249.7M | 341.3M | 358.4M | |
| End Period Cash Flow | 190.3M | 344M | 270.7M | 259.1M | 241M | 253.1M | |
| Change To Inventory | (10.7M) | (2.5M) | (2.6M) | 5.4M | (19.1M) | (20.1M) | |
| Investments | 15M | (102.2M) | (110.2M) | (380.9M) | (126.8M) | (133.1M) | |
| Change Receivables | (69.2M) | (30.5M) | (28.4M) | (162.2M) | (146.0M) | (138.7M) | |
| Change To Netincome | 76.0M | (188.6M) | 142.9M | 266.3M | 306.2M | 321.6M |
Neurocrine Biosciences Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Neurocrine Biosciences or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Neurocrine Biosciences' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Neurocrine stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.13 | |
β | Beta against Dow Jones | 0.51 | |
σ | Overall volatility | 2.81 | |
Ir | Information ratio | -0.03 |
Neurocrine Biosciences Volatility Alert
Neurocrine Biosciences exhibits very low volatility with skewness of -4.42 and kurtosis of 29.29. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Neurocrine Biosciences' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Neurocrine Biosciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Neurocrine Biosciences Fundamentals Vs Peers
Comparing Neurocrine Biosciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Neurocrine Biosciences' direct or indirect competition across all of the common fundamentals between Neurocrine Biosciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as Neurocrine Biosciences or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Neurocrine Biosciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing Neurocrine Biosciences by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Neurocrine Biosciences to competition |
| Fundamentals | Neurocrine Biosciences | Peer Average |
| Return On Equity | 0.14 | -0.31 |
| Return On Asset | 0.1 | -0.14 |
| Profit Margin | 0.14 % | (1.27) % |
| Operating Margin | 0.21 % | (5.51) % |
| Current Valuation | 10.25 B | 16.62 B |
| Shares Outstanding | 99.7 M | 571.82 M |
| Shares Owned By Insiders | 1.02 % | 10.09 % |
| Shares Owned By Institutions | 97.78 % | 39.21 % |
| Number Of Shares Shorted | 3.04 M | 4.71 M |
| Price To Earning | 202.90 X | 28.72 X |
| Price To Book | 4.20 X | 9.51 X |
| Price To Sales | 4.69 X | 11.42 X |
| Revenue | 2.36 B | 9.43 B |
| Gross Profit | 1.59 B | 27.38 B |
| EBITDA | 610.1 M | 3.9 B |
| Net Income | 341.3 M | 570.98 M |
| Cash And Equivalents | 799.4 M | 2.7 B |
| Cash Per Share | 8.31 X | 5.01 X |
| Total Debt | 455.1 M | 5.32 B |
| Debt To Equity | 0.18 % | 48.70 % |
| Current Ratio | 2.48 X | 2.16 X |
| Book Value Per Share | 26.05 X | 1.93 K |
| Cash Flow From Operations | 595.4 M | 971.22 M |
| Short Ratio | 2.02 X | 4.00 X |
| Earnings Per Share | 3.29 X | 3.12 X |
| Price To Earnings To Growth | 0.27 X | 4.89 X |
| Target Price | 164.37 | |
| Number Of Employees | 1.8 K | 18.84 K |
| Beta | 0.35 | -0.15 |
| Market Capitalization | 11.04 B | 19.03 B |
| Total Asset | 3.72 B | 29.47 B |
| Retained Earnings | 29.2 M | 9.33 B |
| Working Capital | 1.22 B | 1.48 B |
Note: Acquisition by Roberts Eiry of 1860 shares of Neurocrine Biosciences subject to Rule 16b-3 [view details]
Neurocrine Biosciences Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Neurocrine . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Neurocrine Biosciences Buy or Sell Advice
When is the right time to buy or sell Neurocrine Biosciences? Buying financial instruments such as Neurocrine Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Neurocrine Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Tech Growth Thematic Idea Now
Tech Growth
Instruments that are typically traded at high earnings multiples compared to their competitors and other sectors and have been known to drive market cycles frequently. The Tech Growth theme has 58 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tech Growth Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.